| Basics |
Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company. The company is engaged in discovering or licensing, developing and commercializing proprietary therapeutics in the fields of oncology, autoimmune and infectious diseases.
|
| IPO Date: |
September 20, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$3.4B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.25 | 2.54%
|
| Avg Daily Range (30 D): |
$0.59 | 1.92%
|
| Avg Daily Range (90 D): |
$0.67 | 2.15%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.43M |
| Avg Daily Volume (30 D): |
.78M |
| Avg Daily Volume (90 D): |
.94M |
| Trade Size |
| Avg Trade Size (Sh.): |
75 |
| Avg Trade Size (Sh.) (30 D): |
80 |
| Avg Trade Size (Sh.) (90 D): |
72 |
| Institutional Trades |
| Total Inst.Trades: |
3,066 |
| Avg Inst. Trade: |
$2.59M |
| Avg Inst. Trade (30 D): |
$2.68M |
| Avg Inst. Trade (90 D): |
$2.31M |
| Avg Inst. Trade Volume: |
.05M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.75M |
| Avg Closing Trade (30 D): |
$1.57M |
| Avg Closing Trade (90 D): |
$1.96M |
| Avg Closing Volume: |
48.43K |
|
|
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q3 2024 |
|
Basic EPS
|
|
$-.04
|
$-.04
|
|
Diluted EPS
|
|
$-.04
|
$-.04
|
|
Revenue
|
$
|
$ 106.49M
|
$ 102.27M
|
|
Gross Profit
|
$
|
$ 68.04M
|
$ 65.7M
|
|
Net Income / Loss
|
$
|
$ -48.44M
|
$ -41.67M
|
|
Operating Income / Loss
|
$
|
$ -56.31M
|
$ -67.85M
|
|
Cost of Revenue
|
$
|
$ 38.45M
|
$ 36.57M
|
|
Net Cash Flow
|
$
|
$ 307.58M
|
$ -14.5M
|
|
PE Ratio
|
|
|
|
|
